A number of presentations at last week’s Conference on Retroviruses and Opportunistic Infections (CROI 2024) looked at whether HIV is starting to develop resistance to dolutegravir, one of the most widely used antiretrovirals in the world.
Guidelines in most parts of the world recommend dolutegravir (or its close cousin, bictegravir) as a component of most people’s first HIV treatment regimen. The World Health Organization recommends it for all populations, and if it wasn’t part of a person’s first-line HIV treatment, it will usually be part of their second-line regimen. The majority of low- and middle-income countries have now switched to a combination pill of tenofovir, lamivudine and dolutegravir (TLD), including South Africa, home of the world’s largest antiretroviral therapy programme.
Read the full story at Aidsmap.
Source : Aidsmap
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.